Ascendis Pharma A/S (ASND) Company Overview

TransCon CNP is comparable to BioMarin's Voxzogo for treating achondroplasia, offering weekly doses instead of daily ones, with plans for regulatory submissions in 2025. The commercial products Skytrofa and Yorvipath are seeing consistent growth, generating $62.4 million in revenue in the third quarter, which supports the effectiveness of the TransCon platform technology. The partnership with Novo for a monthly GLP-1 treatment for obesity could be very significant, featuring $285 million in milestone payments, royalties, and opportunities for expansion.

I'm interested in Ascendis Pharma because of its exciting progress and strong range of products. The company has multiple products that are already on the market, showing it has a solid base and potential for growth. With its varied pipeline, Ascendis seems to have good prospects for future developments and market chances.

COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) has announced that YORVIPATH® (palopegteriparatide; also known as TransCon PTH) is now available by prescription in the United States. This medication is a prodrug of parathyroid hormone (PTH [1-34]) and is taken once a day, providing a steady release of active PTH throughout the day. It is the first and only drug approved by the U.S. Food & Drug Administration (FDA) for treating hypoparathyroidism in adults.

In the first clinical trial for an indication other than growth hormone deficiency, the results for all three starting dose groups of TransCon hGH showed that it has a safety and tolerability profile similar to daily somatropin.

COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) has announced that the U.S. Food & Drug Administration (FDA) will review its supplemental Biologics License Application (sBLA) for TransCon hGH (lonapegsomatropin-tcgd), which is used for adult growth hormone deficiency (GHD) and is sold as SKYTROFA® for children with GHD. The FDA has set a target date of July 27, 2025, for the Prescription Drug User Fee Act (PDUFA).

On December 10, 2024, Er-Kim, a global pharmaceutical company focused on new therapies, revealed that it has renewed its exclusive partnership with Danish biopharmaceutical firm Ascendis Pharma A/S to market three treatments for rare endocrine diseases in certain Eurasian countries. This agreement was first announced in January 2024, when Er-Kim secured the rights to distribute these therapies in Central and Eastern Europe and Turkey.

Ascendis Pharma A/S (ASND) will hold its Q3 2024 Earnings Conference Call on November 14, 2024, at 4:30 PM ET. The call will feature key company leaders, including President and CEO Jan Mikkelsen and CFO Scott Smith. Several financial analysts from major firms will also participate in the discussion.

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) has announced that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food & Drug Administration (FDA). This application is for TransCon hGH, known as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S., which is currently used to treat children with growth hormone deficiency (GHD). The new application aims to extend its use to adults with the same condition.

Lagoa Salgada has been chosen to take part in the European Union's UNDERCOVER Project, which aims to discover hidden critical mineral deposits deep underground using advanced geophysical methods. The project will use techniques like Seismic Reflection, Magnetotellurics, and Electromagnetic Surveys to identify potential mineral deposits. This two-year initiative is fully funded by the EU's Horizon Program and is set to begin in the first quarter of 2025.